W. L. Gore & Associates (Gore) has enrolled the first Australian patients at the Royal Prince Alfred Hospital, Camperdown, into the global registry for endovascular aortic treatment (GREAT).
Devices studied in the registry include the Gore TAG Thoracic Endoprosthesis, Gore Excluder AAA Endoprosthesis and Gore Excluder AAA Endoprosthesis, featuring a C3 delivery system.
The registry is part of the company’s dedication to post-market surveillance, monitoring patient and device performance in an effort to improve clinical practices and patient outcomes.
The Gore Excluder AAA Endoprosthesis is a durable ePTFE bifurcated graft with an outer self-expanding nitinol support structure, used to treat an abdominal aortic aneurysm. Gore’s Excluder AAA Endoprosthesis, featuring the Gore C3 delivery system, provides clinicians with the ability to reposition the Gore Excluder prior to final release from the delivery catheter.
Steven Dubenec, national principal investigator for GREAT in Australia and New Zealand, said GREAT will be a pivotal registry which may advance aortic endovascular therapies in the future.
"Our regional participation in this registry demonstrates the commitment of Australian and New Zealand vascular interventionalists to ongoing advancements in patient care in this field," Dubenec added.
"Our patients can be assured that they are continuing to be offered the optimal technologically advanced, proven and safe therapies for the treatment of aortic disease."
GREAT investigates long-term device performance and associated patient outcomes, which will provide additional details regarding device usage, offering insights into clinical needs for advancing future aortic endovascular therapies.
Gore Medical’s product range includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, as well as staple line reinforcement and sutures for use in vascular, cardiac and general surgery.
